These studies suggest that maintaining hepatic TDAG51 protein levels represents a viable therapeutic approach for the treatment of obesity and insulin resistance associated with nonalcoholic fatty liver disease. This evidence concerns the gene PHLDA1 and obesity due to melanocortin 4 receptor deficiency.